Massachusetts' plan for $1B in life science investment stalls in state...
Massachusetts Gov. Maura Healey’s proposal to invest another $1 billion in life sciences over the next 10 years has been imperiled after failing to make it through the state’s legislative body before...
View ArticleDoses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA...
Doses of Eli Lilly’s blockbuster weight loss and diabetes drugs that were listed as in short supply no longer are, according to the FDA’s database that tracks drugs in limited supply. The agency’s...
View ArticleAdvisory committee votes in favor of Zevra Therapeutics' rare genetic disease...
A panel of outside advisors to the FDA voted 11-5 in favor of Zevra Therapeutics’ drug for a rare genetic condition called Niemann-Pick disease type C, saying that it is effective based on current...
View ArticleEisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View ArticleA new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’...
Red Queen Therapeutics is emerging from stealth with $55 million from venture capital group Apple Tree Partners, and plans to develop treatments for a swathe of viral infections including Covid-19 and...
View ArticleClik here to view.
Merck enlists partner Daiichi Sankyo to develop T cell engager from Harpoon...
Daiichi Sankyo is paying Merck $170 million upfront to snag joint development and commercialization rights to a Phase 1/2 T cell engager that the New Jersey pharma giant got in its Harpoon acquisition...
View ArticleJapanese government grants Shinobi $59M for cell therapy development
Cell therapy biotech Shinobi Therapeutics has pulled in $59 million in funding from a Japanese government grant. The pharma company also expanded its Series A round from last year. The Japanese Agency...
View ArticleClik here to view.
Exclusive: TCG, DCVC and Lux back new autoimmune biotech from Kallyope...
A stealth biotech from repeat collaborators has assembled the latest industry megaround. New York-based NILO Therapeutics has put together a $101 million Series A, Tim Kutzkey, a board member and...
View ArticleGenentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy
An experimental Alzheimer’s drug and its designer are getting a second chance. On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic repressor to prevent the production...
View ArticleClik here to view.
Hims takes steps to lock up drug supply for its booming weight loss business
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Hims CEO Andrew Dudum did his best Monday to reassure investors that the digital health startup’s...
View ArticleArie Belldegrun and team unveil $600M life sciences credit firm amid...
A new $600-plus million credit firm was unveiled Tuesday morning from Arie Belldegrun and other well-known life sciences names. Rather than create another venture capital firm, the Kite Pharma founder...
View ArticleClik here to view.
Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after...
Aerium Therapeutics has ceased operations, ending its mission to bring to market new antibodies to protect immunocompromised people from Covid-19, develop highly sought-after long Covid treatments and...
View ArticleBioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets
Plus, news about Tenax Therapeutics: BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the market.” The company tried to...
View ArticleClik here to view.
Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B
Eisai is paying SEED Therapeutics an undisclosed amount upfront in a deal worth up to $1.5 billion to develop new ‘molecular glue’-based therapies for neurodegenerative diseases and cancer. The...
View ArticleBicycle Therapeutics focuses pipeline and streamlines leadership team
Bicycle Therapeutics spelled out its pipeline priorities on Tuesday, adding that it will be looking for collaborators for its immune-oncology pipeline. It is also narrowing its executive team. The...
View ArticleGSK wins second Zantac cancer case to go to trial
GSK was found not liable in the second jury trial involving the company’s heartburn medication, Zantac. The company said in a statement Monday that the decision in Illinois state court is “consistent...
View ArticleClik here to view.
TPG reveals $580M life sciences fund, which has already backed multiple biotechs
Another large asset manager is further boosting its presence in the biotech and life sciences with a large fund for startups. The private equity manager TPG said Tuesday morning it closed a $580...
View ArticleNovo Nordisk goes after more compounders, expanding GLP-1 lawsuit campaign
Novo Nordisk is turning up the heat on compounding pharmacies making versions of its blockbuster. Late last week, the company filed 11 new lawsuits against med spas, weight loss clinics and telehealth...
View ArticleClik here to view.
CDC chief says new RSV guidance was meant to be ‘clear’ and ‘actionable’
CDC Director Mandy Cohen says that new guidance for respiratory syncytial virus (RSV) vaccination was meant to be easier to implement than last year’s advice, explaining some of the thinking behind a...
View Article